瑞士Actelion制药公司选择了一条别人未走过的忠诚营销之路。这一选择始于该公司从制药业巨人罗氏公司分离出来,专注研究几项分子制药的应用。罗氏认为这些药品的市场需求有限,而不愿继续研究。然而,十年后正是通过在未获满足的药品领域进行研究开发和推广,Actelion建立起了一个繁荣的跨国制药公 Actelion Pharmaceuticals Switzerland chose a path of loyalty marketing that others have not yet gone through. The choice began with the company’s separation from the pharmaceutical giant Roche, focusing on the application of several molecular pharmaceuticals. Roche believes that the market demand for these drugs is limited, rather than continue to study. However, just ten years later it was through research, development and promotion in the unmet chemical sector that Actelion built a prosperous multinational pharmaceutical company